Royalty Pharma PLC (NASDAQ:RPRX – Get Free Report) EVP Christopher Hite sold 100,000 shares of Royalty Pharma stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $68.15, for a total value of $6,815,000.00. Following the transaction, the executive vice president directly owned 177,523 shares in the company, valued at approximately $12,098,192.45. The trade was a 36.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Christopher Hite also recently made the following trade(s):
- On Tuesday, September 22nd, Christopher Hite sold 100,000 shares of Royalty Pharma stock. The stock was sold at an average price of $58.53, for a total value of $5,853,000.00.
Royalty Pharma Stock Down 0.0%
Shares of Royalty Pharma stock traded down $0.01 during midday trading on Wednesday, hitting $68.67. The company’s stock had a trading volume of 3,192,451 shares, compared to its average volume of 3,426,408. Royalty Pharma PLC has a 1-year low of $37.31 and a 1-year high of $70.37. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $39.39 billion, a P/E ratio of 57.23, a PEG ratio of 1.36 and a beta of 0.37. The stock has a 50-day simple moving average of $61.77 and a 200-day simple moving average of $54.81.
Royalty Pharma Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a $0.2350 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $0.94 dividend on an annualized basis and a yield of 1.4%. Royalty Pharma’s dividend payout ratio (DPR) is 78.33%.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of RPRX. Renaissance Technologies LLC acquired a new stake in shares of Royalty Pharma in the 1st quarter valued at about $37,941,000. Bank of America Corp DE boosted its position in shares of Royalty Pharma by 29.0% during the first quarter. Bank of America Corp DE now owns 3,495,846 shares of the biopharmaceutical company’s stock worth $167,696,000 after buying an additional 786,921 shares during the period. Carmignac Gestion acquired a new position in shares of Royalty Pharma during the first quarter worth about $30,279,000. Congress Asset Management Co. bought a new stake in Royalty Pharma in the 3rd quarter valued at approximately $30,761,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new position in Royalty Pharma during the 3rd quarter worth approximately $24,225,000. Institutional investors and hedge funds own 54.35% of the company’s stock.
Analyst Ratings Changes
RPRX has been the subject of a number of analyst reports. TD Cowen raised their price target on shares of Royalty Pharma from $68.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday. Bank of America reiterated a “buy” rating on shares of Royalty Pharma in a research note on Wednesday, August 5th. Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday. Morgan Stanley increased their target price on Royalty Pharma from $65.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Finally, Citigroup raised their target price on Royalty Pharma from $70.00 to $78.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. One research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $65.00.
Get Our Latest Stock Report on Royalty Pharma
About Royalty Pharma
Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.
Featured Stories
- Five stocks we like better than Royalty Pharma
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
